Skip to main content

A Mobile App to Address Sexual Dysfunction in HSCT Survivors: Areej El-Jawahri, MD

After receiving hematopoietic stem cell transplantation (HSCT), many survivors experience issues with sexual dysfunction which can impact their quality of life. To address this challenge, Dr. Areej El-Jawahri, Director of the Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital (MGH), and her team developed a multimodal mobile app as an intervention for sexual health concerns after transplant. After presenting this research at the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. El-Jawahri sat down with Oncology Data Advisor to further explain the app's development and efficacy, as well as additional ways it can be used to improve quality of life for transplant survivors in the future.  

Continue reading

Veno-Occlusive Disease: An Interview with Phyllis McKiernan, APN, MSN, OCN® and Michelle N. Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON

Veno-occlusive disease (VOD) is a potentially life-threatening complication of hematopoietic stem cell transplant. In patients with severe cases, the mortality rate has been estimated to be greater than 80%. In this exclusive interview, Phyllis McKiernan, APN, MSN, OCN and Michelle Rickard, DNP, CPNP-AC, CHPPN, BMTCN, CPON spoke with i3 Health about challenges, patient education strategies, and best practices in nursing management of adult and pediatric patients with VOD.​

Continue reading

Navigating the Therapeutic Landscape for Patients Undergoing HSCT With Sergio Giralt, MD

Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow HSCT in older patients and alternative graft sources that afford a donor for nearly all patients who req...

Continue reading

Herpes Zoster (Shingles) Vaccination After Autologous HSCT

​A phase 3 clinical trial reports that two doses of the adjuvanted recombinant zoster vaccine reduce the incidence of herpes zoster, commonly known as shingles, following autologous hematopoietic stem cell transplantation (HSCT). Patients receiving high-dose chemotherapy for certain types of malignancies, including multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia, neuroblastoma, and germ cell tumors, are often administered autologous HSCT in order to replenish the...

Continue reading

HSCT: Improving Communication Between the Transplant Center and the Oncologist With Miguel-Angel Perales, MD

While hematopoietic stem cell transplant (HSCT) offers a curative treatment option for many patients, oncologists face unique challenges, including the underutilization of transplant, the need for improved communication between the transplant center and the community oncologist, and the implementation of CAR T-cell therapy. In this interview with i3 Health, Miguel-Angel Perales, MD, addresses these challenges and discusses the importance of clinical trial enrollment and innovative programs that ...

Continue reading

In High-Risk Neuroblastoma, Tandem Transplant Is Superior

A randomized clinical trial reports that in patients with neuroblastoma, tandem autologous stem cell transplant improves outcomes compared with single transplant. Neuroblastoma, a malignancy of the developing sympathetic nervous system, is responsible for around 10% to 12% of childhood cancer deaths. For the 43% of patients who present with high-risk disease, which involves either widespread metastasis in patients over the age of 18 months and/or amplification of the MYCN oncogene, the standard ...

Continue reading